Solaxa Inc. Begins Operations as a Public Benefit Corporation
Bethesda, MD; February 24, 2022 – Solaxa Inc. today announces its amended incorporation under the laws of Delaware as a Public Benefit Corporation with the purpose of restoring the lives of patients with nerve injuries by developing and marketing neuro-regenerative therapies that are impactful and accessible. The company had previously operated as Peripheral Therapeutics Inc., since its original incorporation on February 3, 2021.
The company’s Founder and Chief Executive Officer, Christian Walker, noted that “Solaxa will leverage impart new discoveries regarding the therapeutic utility of ion channel blockers to develop and bring to market new therapies for underserved patient populations.” Solaxa is Mr. Walker’s third start-up experience in the neurology field following prior leadership roles at Axogen and Neuraptive as well as Walter Reed Military Medical Center.
Solaxa’s initial product development efforts will focus on continuation of scientific discoveries made by its two other co-founders. Mark Noble, Ph,D., Professor of Biomedical Genetics and Neuroscience at the University of Rochester, and John Elfar, M.D., MBA, Professor and Chair of Orthopedics at the University of Arizona.
About Solaxa
Solaxa is an exciting, clinical-ready biopharmaceutical company developing treatments for rare neurodegenerative diseases and acute nerve injuries. The company is developing both novel and reformulated drugs to restore nerve function by targeting ion channels. Solaxa is organized as a public benefit corporation, enabling it to focus on developing accessible and impactful treatments while prioritizing societal health alongside corporate profitability. For more information, visit Solaxa.com.
CONTACT:
Christian Walker
Solaxa Inc.